Mepro

What Mepro does

Mepro Pharmaceuticals Pvt. Ltd. is an Indian pharmaceutical manufacturer founded in 1961 and headquartered in Mumbai, operating four state-of-the-art manufacturing facilities across Gujarat (Surendranagar Units I and II, Vadodra Unit III) and Uttarakhand (Dehradun under subsidiary MeproMax Lifesciences). The company produces a broad generic and specialty pharmaceutical portfolio spanning solid orals (tablets, capsules, sachets), semisolids (creams, ointments, gels), sterile injectables (ampoules, vials, lyophilised vials, prefilled syringes), and dry powder antibiotic injectables (cephalosporins and carbapenems). Its R&D platform applies Quality-by-Design principles, process chemistry, lyophilisation, controlled/sustained/modified release technologies, novel drug delivery systems, bioequivalence studies, and Six Sigma manufacturing to develop complex generics, sterile formulations, and orphan drugs across therapeutic areas including antibiotics, antidiabetics, cardiovascular, analgesics, and dermatology. The portfolio comprises 350+ products and 1000+ registrations across regulated and semi-regulated markets.

Mepro operates four interlocking revenue streams. (1) Generics licensing and CMO partnerships — IP-driven product licensing, marketing/distribution agreements, and contract manufacturing with large multinational pharmaceutical companies across the development-to-supply-chain value chain, with a stated track record of capturing 35% UK market share for three products in the launch year and EU GMP, UK MHRA, TGA Australia, PIC/s, and WHO GMP certifications. (2) Branded generics distribution through large regional distributors in domestic India and semi-regulated markets across 40+ countries. (3) Institutional supply of essential medicines to UN organisations — UNICEF, UNRWA, UNPFA, WHO, Medecins Sans Frontieres, and IDA Foundation — including a long-term supply agreement covering 10 products for ~5.6 million Palestinian refugees. (4) Grant-funded R&D for neglected tropical diseases, including recurring USAID funding supporting a Soil Transmitted Helminths treatment programme that reaches ~42 million children annually and a WHO Prequalification filing for first generic entry into the WHO PQ Programme.

The company employs 1000+ staff, holds a stated zero-failure record across hundreds of regulatory and client audits, and operates with combined capacity of approximately 13 million tablets/day and 4.5 million capsules/day plus large-volume sterile injectable manufacturing. Mepro is privately held with no disclosed parent company or external equity sponsor; ownership remains founder/management-controlled, with growth funded through manufacturing cash flow, capacity expansion across Gujarat and Uttarakhand, and non-dilutive grants rather than venture or private equity capital.

Name

Mepro

Legal name

Mepro Pharmaceuticals Pvt. Ltd.

Website

https://mepro.in

Company type

Private

Founded year

1961

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Mepro Pharmaceuticals is a Mumbai-headquartered, privately held Indian manufacturer producing generics, complex generics, sterile injectables and dry powder antibiotics across four plants, serving multinational partners, regional distributors and UN agencies in 40+ countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIABAH

Generic Finished Dosage Form (FDF) Manufacturing

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

SECONDARYHLAIACAO

Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Generic pharmaceuticals manufacturing
• Sterile injectables production
• Contract manufacturing services
• Complex generics development
• Pharmaceutical formulation licensing

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Generics Business / CMO: IP-driven product licensing and marketing/distribution partnerships. Custom-made end-to-end solutions from development to supply chain management. Contract manufacturing (CMO) services for large multinationals with licensed products.
2. Branded Generics: Enhancing presence in domestic and semi-regulated markets through robust partnerships with large distributors in each country. 1000+ registrations across Asia, Africa, Europe, Latin America and Central America.
3. Institutional Business: Manufacturing and supply of drugs for institutional businesses including funded projects and global procurement agencies. Approved supplier to UN organizations, providing healthcare at affordable cost.
4. USAID Grant: Grant funding from USAID for development and commercialization of drugs in neglected tropical diseases segment.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

Core offering

Mepro Pharmaceuticals is a vertically integrated pharmaceutical manufacturer that develops, produces, and supplies a broad portfolio of generic and specialty medicines across multiple dosage forms including tablets, capsules, creams/ointments/gels, sterile injectables (ampoules, vials, lyophilised vials, prefilled syringes), sachets, and dry powder cephalosporin and carbapenem antibiotics. The company operates four state-of-the-art manufacturing facilities in India and serves regulated markets, semi-regulated markets across 40+ countries, UN agencies, and multinational pharmaceutical clients through licensing, CMO, and branded generics channels.

Product overview

Mepro Pharmaceuticals is a vertically integrated pharmaceutical company that develops and manufactures a broad portfolio of generic and specialty pharmaceutical products. The company operates 4 state-of-the-art manufacturing facilities across India producing tablets, capsules, creams/ointments/gels, sterile injectables (ampoules, vials, lyophilized vials, prefilled syringes), sachets, and dry powder antibiotics (cephalosporins and carbapenems). The product portfolio spans multiple therapeutic categories including analgesics, antibiotics, antidiabetics, cardiovascular drugs, and dermatological products. Mepro serves regulated markets (EU, UK, US, Australia, Canada) and semi-regulated markets across 40+ countries through generics licensing, contract manufacturing (CMO), branded generics, and institutional business channels including supply to UN agencies.

Differentiator

Problem solved

Functional benefit

Brands

• MeproMax Lifesciences: Subsidiary company manufacturing tablets, capsules, creams, ointments, and Dry Powder Carbapenem Injectables for the Indian pharmaceutical market.

Products and services

• Tablets Conventional and specialized tablet formulations including taste-masked, controlled-release, sustained-release, modified-release, effervescent, and mouth-dissolving tablets manufactured across Mepro's facilities.
• Capsules Hard gelatin capsules containing various pharmaceutical formulations for oral delivery.
• Creams & Ointments/Gels Topical formulations for dermatological applications including creams, ointments, and gels.
• Sterile Injectables Sterile injectable products including ampoules, vials, lyophilised vials, and prefilled syringes for small volume parenterals.
• Sachets Powder formulations in sachet packaging for oral administration.
• Dry Powder Cephalosporin Injectables Dry powder injectable formulations of cephalosporin antibiotics for parenteral administration.
• Dry Powder Carbapenem Injectables Dry powder injectable formulations of carbapenem antibiotics for treating severe infections.
• Complex Generics Technically complex generic pharmaceutical products including novel drug delivery systems, complex generics, and orphan drugs developed for regulated-market licensing and CMO partnerships.

Quantifiable outcome

• 35% market share captured for 3 products in the UK in its 1st year of inception
• +2 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Eight partnerships are on record, tiered core.

• UNICEFcoreStrategic or Co-development PartnerMepro is an approved supplier to UNICEF, providing essential medicines for global procurement. This long-term partnership supports humanitarian healthcare needs worldwide.
• UNRWAcoreStrategic or Co-development PartnerMepro has been a partner of choice to UNRWA for more than a decade, supporting healthcare needs of approximately 5.6 million Palestinian refugees across West Bank, Gaza, Lebanon, Jordan and Syria. Partnership covers 10 products in acute and chronic segments under long-term supply agreement.
• UNPFAcoreStrategic or Co-development PartnerMepro is an approved supplier to UNPFA (United Nations Population Fund) for reproductive health supplies and medicines.
• WHOcoreStrategic or Co-development PartnerMepro is an approved supplier to WHO and has scheduled WHO PQ (Prequalification) filing for a product making its first Generic entry into WHO's PQ Programme.
• Medecins Sans FrontierescoreStrategic or Co-development PartnerMepro is an approved supplier to Medecins Sans Frontieres (Doctors Without Borders) for humanitarian medical supplies and emergency medicines.
• IDA FoundationcoreStrategic or Co-development PartnerMepro is an approved supplier to IDA Foundation, a global health procurement agency serving developing countries.
• Global Non-profit Organization (STH Treatment)coreStrategic or Co-development PartnerMepro has tied up with a global non-profit organisation for manufacturing and supply of a drug for Soil Transmitted Helminths (STH) treatment therapy. Through this partnership's distribution network, approximately 42 million children aged 12-59 months are treated each year.
• Large Multinational Pharmaceutical Companies (CMO)coreChannel Partner/ Reseller/ DistributorMepro serves as a partner of choice for several large multinationals looking to contract manufacture (CMO) their licensed products. Scalability and conflict-free manufacturing history make Mepro preferred for CMO arrangements.

Scale indicators9 records

Recent moves16 records

Expansion highlights6 records

Direct peers

• Unichem Laboratories: Indian pharmaceutical manufacturer with API plus finished dosage forms and international generic presence—comparable in operating model and therapeutic mix to Mepro.
• Granules India: Indian vertically integrated generics manufacturer with strong global distribution, comparable in its focus on solid oral dosages and emerging export footprint.
• Alkem Laboratories: India-based generic pharmaceutical manufacturer with multi-therapy portfolio and global presence across regulated and semi-regulated markets, comparable in scale and product breadth to Mepro.
• Emcure Pharmaceuticals: India-headquartered, privately rooted generic and complex generics manufacturer with global CMO partnerships and institutional supply across emerging markets—directly comparable business model and customer base to Mepro.
• Strides Pharma Science: Indian generics manufacturer with regulated-market (US/EU/AU) focus and strong institutional/tender business, closely aligned with Mepro's regulated-plus-institutional dual GTM.
• Indoco Remedies: Smaller Indian generics manufacturer focused on regulated markets and complex generics with UK/EU regulatory footprint—an analogous mid-cap peer to Mepro's profile.

Broad incumbents

• Dr. Reddy's Laboratories: Established Indian generics manufacturer with global branded and complex generics franchise including sterile injectables—a relevant broader incumbent for comparison.
• Cipla: Major Indian pharmaceutical company with broad generics and institutional health footprint; comparable end-markets and therapeutic categories but substantially larger and more diversified than Mepro.
• Aurobindo Pharma: Large Indian generics manufacturer with global footprint across US/EU and emerging markets—overlaps significantly with Mepro's portfolio but operates at materially greater scale.
• Lupin: Indian generics major with regulated-market presence in US, EU and emerging markets, overlapping with Mepro's regulated market ambitions but at much larger scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mepro